{"id":"W4411027965","doi":"10.1200/jco.2025.43.17_suppl.lba109","title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Triple-negative breast cancer; Breast cancer; Chemotherapy; Cancer; Oncology; Internal medicine; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00275467,0.001481753,0.001884878,0.0005288198,0.0002641746,0.0009235858,0.001089123,0.001479861,0.005394145],"category_scores_gemma":[0.001556298,0.0005588756,0.001880893,0.0004789504,0.0009007328,0.0010556,0.0004947685,0.002906898,0.0009250089],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001049525,"about_ca_system_score_gemma":0.001109374,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009440158,"about_ca_topic_score_gemma":0.002643688,"domain_scores_codex":[0.9991834,0.0005216957,0.00003897082,0.00009123749,0.00004358286,0.0001211346],"domain_scores_gemma":[0.9987974,0.0003243358,0.0003468082,0.00008770986,0.00004232692,0.0004014675],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9778767,0.007454988,0.0007294377,0.0002216916,0.000564379,0.00002177371,0.00002497794,0.0003776014,0.002267498,0.00004841671,0.0006621312,0.009750475],"study_design_scores_gemma":[0.7466354,0.2436846,0.005305952,0.00004519839,0.001136604,0.00005124062,0.00003183539,0.0006917887,0.001037412,0.0001987298,0.001165737,0.00001553289],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909766,0.003282502,0.0002958887,0.0006699021,0.0003755138,0.001807461,0.001086546,0.00006227128,0.001443386],"genre_scores_gemma":[0.9911484,0.001833242,0.0007090699,0.0008304926,0.0003427488,0.001762242,0.001166825,0.0000231035,0.002183822],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005394145,"threshold_uncertainty_score":0.01804519,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03209540618474122,"score_gpt":0.4260614781526635,"score_spread":0.3939660719679223,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}